Accelerated Theta Burst Transcranial Magnetic Stimulation for Refractory Depression in Autism Spectrum Disorder / Elizabeth BLANK in Journal of Autism and Developmental Disorders, 55-3 (March 2025)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 55-3 (March 2025) . - p.940-954 Titre : Accelerated Theta Burst Transcranial Magnetic Stimulation for Refractory Depression in Autism Spectrum Disorder Type de document : texte imprimé Auteurs : Elizabeth BLANK, Auteur ; Donald L. GILBERT, Auteur ; Steve W. WU, Auteur ; Travis LARSH, Auteur ; Rana ELMAGHRABY, Auteur ; Rui LIU, Auteur ; Elizabeth SMITH, Auteur ; Grace WESTERKAMP, Auteur ; Yanchen LIU, Auteur ; Paul S. HORN, Auteur ; Ethan GREENSTEIN, Auteur ; John A. SWEENEY, Auteur ; Craig A. ERICKSON, Auteur ; Ernest V. PEDAPATI, Auteur Article en page(s) : p.940-954 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : Major depressive disorder (MDD) disproportionately affects those living with autism spectrum disorder (ASD) and is associated with significant impairment and treatment recidivism. En ligne : https://doi.org/10.1007/s10803-024-06244-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=548 [article] Accelerated Theta Burst Transcranial Magnetic Stimulation for Refractory Depression in Autism Spectrum Disorder [texte imprimé] / Elizabeth BLANK, Auteur ; Donald L. GILBERT, Auteur ; Steve W. WU, Auteur ; Travis LARSH, Auteur ; Rana ELMAGHRABY, Auteur ; Rui LIU, Auteur ; Elizabeth SMITH, Auteur ; Grace WESTERKAMP, Auteur ; Yanchen LIU, Auteur ; Paul S. HORN, Auteur ; Ethan GREENSTEIN, Auteur ; John A. SWEENEY, Auteur ; Craig A. ERICKSON, Auteur ; Ernest V. PEDAPATI, Auteur . - p.940-954. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 55-3 (March 2025) . - p.940-954 Index. décimale : PER Périodiques Résumé : Major depressive disorder (MDD) disproportionately affects those living with autism spectrum disorder (ASD) and is associated with significant impairment and treatment recidivism. En ligne : https://doi.org/10.1007/s10803-024-06244-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=548

Altered frontal connectivity as a mechanism for executive function deficits in fragile X syndrome / Lauren M. SCHMITT in Molecular Autism, 13 (2022)  

Public ISBD [article]  inMolecular Autism > 13 (2022) . - 47 p. Titre : Altered frontal connectivity as a mechanism for executive function deficits in fragile X syndrome Type de document : texte imprimé Auteurs : Lauren M. SCHMITT, Auteur ; Joy LI, Auteur ; Rui LIU, Auteur ; Paul S. HORN, Auteur ; John A. SWEENEY, Auteur ; Craig A. ERICKSON, Auteur ; Ernest V. PEDAPATI, Auteur Article en page(s) : 47 p. Langues : Anglais (eng) Mots-clés : Child  Male  Humans  Female  Fragile X Syndrome  Executive Function  Autism Spectrum Disorder  Electroencephalography/methods  Brain  Connectivity  Eeg  Electroencephalography  Fxs  Fragile X syndrome  commercial or financial relationships that could be construed as a potential  conflict of interest for the current manuscript. Index. décimale : PER Périodiques Résumé : BACKGROUND: Fragile X syndrome (FXS) is the leading inherited monogenic cause of intellectual disability and autism spectrum disorder. Executive function (EF), necessary for adaptive goal-oriented behavior and dependent on frontal lobe function, is impaired in individuals with FXS. Yet, little is known how alterations in frontal lobe neural activity is related to EF deficits in FXS. METHODS: Sixty-one participants with FXS (54% males) and 71 age- and sex-matched typically-developing controls (TDC; 58% males) completed a five-minute resting state electroencephalography (EEG) protocol and a computerized battery of tests of EF, the Test of Attentional Performance for Children (KiTAP). Following source localization (minimum-norm estimate), we computed debiased weighted phase lag index (dWPLI), a phase connectivity value, for pairings between 18 nodes in frontal regions for gamma (30-55 Hz) and alpha (10.5-12.5 Hz) bands. Linear models were generated with fixed factors of group, sex, frequency, and connection. Relationships between frontal connectivity and EF variables also were examined. RESULTS: Individuals with FXS demonstrated increased gamma band and reduced alpha band connectivity across all frontal regions and across hemispheres compared to TDC. After controlling for nonverbal IQ, increased error rates on EF tasks were associated with increased gamma band and reduced alpha band connectivity. LIMITATIONS: Frontal connectivity findings are limited to intrinsic brain activity during rest and may not generalize to frontal connectivity during EF tasks or everyday function. CONCLUSIONS: We report gamma hyper-connectivity and alpha hypo-connectivity within source-localized frontal brain regions in FXS compared to TDC during resting-state EEG. For the first time in FXS, we report significant associations between EF and altered frontal connectivity, with increased error rate relating to increased gamma band connectivity and reduced alpha band connectivity. These findings suggest increased phase connectivity within gamma band may impair EF performance, whereas greater alpha band connectivity may provide compensatory support for EF. Together, these findings provide important insight into neurophysiological mechanisms of EF deficits in FXS and provide novel targets for treatment development. En ligne : http://dx.doi.org/10.1186/s13229-022-00527-0 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=491 [article] Altered frontal connectivity as a mechanism for executive function deficits in fragile X syndrome [texte imprimé] / Lauren M. SCHMITT, Auteur ; Joy LI, Auteur ; Rui LIU, Auteur ; Paul S. HORN, Auteur ; John A. SWEENEY, Auteur ; Craig A. ERICKSON, Auteur ; Ernest V. PEDAPATI, Auteur . - 47 p. Langues : Anglais (eng) in Molecular Autism > 13 (2022) . - 47 p. Mots-clés : Child  Male  Humans  Female  Fragile X Syndrome  Executive Function  Autism Spectrum Disorder  Electroencephalography/methods  Brain  Connectivity  Eeg  Electroencephalography  Fxs  Fragile X syndrome  commercial or financial relationships that could be construed as a potential  conflict of interest for the current manuscript. Index. décimale : PER Périodiques Résumé : BACKGROUND: Fragile X syndrome (FXS) is the leading inherited monogenic cause of intellectual disability and autism spectrum disorder. Executive function (EF), necessary for adaptive goal-oriented behavior and dependent on frontal lobe function, is impaired in individuals with FXS. Yet, little is known how alterations in frontal lobe neural activity is related to EF deficits in FXS. METHODS: Sixty-one participants with FXS (54% males) and 71 age- and sex-matched typically-developing controls (TDC; 58% males) completed a five-minute resting state electroencephalography (EEG) protocol and a computerized battery of tests of EF, the Test of Attentional Performance for Children (KiTAP). Following source localization (minimum-norm estimate), we computed debiased weighted phase lag index (dWPLI), a phase connectivity value, for pairings between 18 nodes in frontal regions for gamma (30-55 Hz) and alpha (10.5-12.5 Hz) bands. Linear models were generated with fixed factors of group, sex, frequency, and connection. Relationships between frontal connectivity and EF variables also were examined. RESULTS: Individuals with FXS demonstrated increased gamma band and reduced alpha band connectivity across all frontal regions and across hemispheres compared to TDC. After controlling for nonverbal IQ, increased error rates on EF tasks were associated with increased gamma band and reduced alpha band connectivity. LIMITATIONS: Frontal connectivity findings are limited to intrinsic brain activity during rest and may not generalize to frontal connectivity during EF tasks or everyday function. CONCLUSIONS: We report gamma hyper-connectivity and alpha hypo-connectivity within source-localized frontal brain regions in FXS compared to TDC during resting-state EEG. For the first time in FXS, we report significant associations between EF and altered frontal connectivity, with increased error rate relating to increased gamma band connectivity and reduced alpha band connectivity. These findings suggest increased phase connectivity within gamma band may impair EF performance, whereas greater alpha band connectivity may provide compensatory support for EF. Together, these findings provide important insight into neurophysiological mechanisms of EF deficits in FXS and provide novel targets for treatment development. En ligne : http://dx.doi.org/10.1186/s13229-022-00527-0 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=491

Brief Report: A Double-Blind, Placebo-Controlled, Crossover, Proof-of-Concept Study of Minocycline in Autism Spectrum Disorder / Craig A. ERICKSON in Journal of Autism and Developmental Disorders, 55-9 (September 2025)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 55-9 (September 2025) . - p.3387-3394 Titre : Brief Report: A Double-Blind, Placebo-Controlled, Crossover, Proof-of-Concept Study of Minocycline in Autism Spectrum Disorder Type de document : texte imprimé Auteurs : Craig A. ERICKSON, Auteur ; Rebecca C. SHAFFER, Auteur ; Meredith WILL, Auteur ; Lauren M. SCHMITT, Auteur ; Paul HORN, Auteur ; Kathy HIRST, Auteur ; Ernest V. PEDAPATI, Auteur ; Nicole OBER, Auteur ; Rameshwari V. TUMULURU, Auteur ; Benjamin L. HANDEN, Auteur ; David Q. BEVERSDORF, Auteur Article en page(s) : p.3387-3394 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : Neuroinflammatory mechanisms have been implicated in the pathophysiology of autism spectrum disorder (ASD). Minocycline is a matrix metalloproteinase inhibitor 9 (MMP9) inhibitor tetracycline antibiotic with known anti-inflammatory properties. In preclinical animal models of ASD, minocycline has demonstrated potential positive effects on phenotypes that may have relevance to ASD. We conducted the first placebo-controlled study of minocycline in ASD. This double-blind, placebo-controlled crossover trial employed four week treatment periods with a two week washout period. Twenty-four 12-22 year olds (mean age 17.4 years; range 12.9-22.5 years) with ASD were enrolled. Overall minocycline was well tolerated. No minocycline-associated clinical changes were noted with treatment on any performance or clinician or caregiver completed measures were noted. We hypothesize that either minocycline does not have potential therapeutic effects in ASD or our project was underpowered to define potential subject subgroups who may potentially respond positively to this drug. En ligne : https://doi.org/10.1007/s10803-023-06132-1 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=566 [article] Brief Report: A Double-Blind, Placebo-Controlled, Crossover, Proof-of-Concept Study of Minocycline in Autism Spectrum Disorder [texte imprimé] / Craig A. ERICKSON, Auteur ; Rebecca C. SHAFFER, Auteur ; Meredith WILL, Auteur ; Lauren M. SCHMITT, Auteur ; Paul HORN, Auteur ; Kathy HIRST, Auteur ; Ernest V. PEDAPATI, Auteur ; Nicole OBER, Auteur ; Rameshwari V. TUMULURU, Auteur ; Benjamin L. HANDEN, Auteur ; David Q. BEVERSDORF, Auteur . - p.3387-3394. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 55-9 (September 2025) . - p.3387-3394 Index. décimale : PER Périodiques Résumé : Neuroinflammatory mechanisms have been implicated in the pathophysiology of autism spectrum disorder (ASD). Minocycline is a matrix metalloproteinase inhibitor 9 (MMP9) inhibitor tetracycline antibiotic with known anti-inflammatory properties. In preclinical animal models of ASD, minocycline has demonstrated potential positive effects on phenotypes that may have relevance to ASD. We conducted the first placebo-controlled study of minocycline in ASD. This double-blind, placebo-controlled crossover trial employed four week treatment periods with a two week washout period. Twenty-four 12-22 year olds (mean age 17.4 years; range 12.9-22.5 years) with ASD were enrolled. Overall minocycline was well tolerated. No minocycline-associated clinical changes were noted with treatment on any performance or clinician or caregiver completed measures were noted. We hypothesize that either minocycline does not have potential therapeutic effects in ASD or our project was underpowered to define potential subject subgroups who may potentially respond positively to this drug. En ligne : https://doi.org/10.1007/s10803-023-06132-1 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=566

Brief Report: Feasibility of the Probabilistic Reversal Learning Task as an Outcome Measure in an Intervention Trial for Individuals with Autism Spectrum Disorder / Lauren M. SCHMITT in Journal of Autism and Developmental Disorders, 52-9 (September 2022)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 52-9 (September 2022) . - p.4191-4199 Titre : Brief Report: Feasibility of the Probabilistic Reversal Learning Task as an Outcome Measure in an Intervention Trial for Individuals with Autism Spectrum Disorder Type de document : texte imprimé Auteurs : Lauren M. SCHMITT, Auteur ; John A. SWEENEY, Auteur ; Craig A. ERICKSON, Auteur ; Rebecca SHAFFER, Auteur Article en page(s) : p.4191-4199 Langues : Anglais (eng) Mots-clés : Autism Spectrum Disorder/psychology/therapy  Feasibility Studies  Humans  Outcome Assessment, Health Care  Reproducibility of Results  Reversal Learning/physiology  Autism spectrum disorder  Cognitive flexibility  Outcome measurement  Reversal learning  training (RS, LS). Index. décimale : PER Périodiques Résumé : Cognitive flexibility deficits are a hallmark feature of autism spectrum disorder (ASD), but few evidence-based behavioral interventions have successfully addressed this treatment target. Outcome measurement selection may help account for previous findings. The probabilistic reversal learning task (PRL) is a measure of cognitive flexibility previously validated for use in ASD, but its use as an outcome measure has not yet been assessed. The current study examined the feasibility, reproducibility, and sensitivity of PRL in a within-subjects trial of Regulating Together, a group-based intervention targeting emotion regulation. We demonstrated the PRL is highly feasible, showed test-retest reproducibility, and is sensitive to detect change following the intervention. Our findings demonstrate the PRL task may be a useful outcome measure of cognitive flexibility in future intervention trials in ASD. En ligne : http://dx.doi.org/10.1007/s10803-021-05288-y Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=486 [article] Brief Report: Feasibility of the Probabilistic Reversal Learning Task as an Outcome Measure in an Intervention Trial for Individuals with Autism Spectrum Disorder [texte imprimé] / Lauren M. SCHMITT, Auteur ; John A. SWEENEY, Auteur ; Craig A. ERICKSON, Auteur ; Rebecca SHAFFER, Auteur . - p.4191-4199. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 52-9 (September 2022) . - p.4191-4199 Mots-clés : Autism Spectrum Disorder/psychology/therapy  Feasibility Studies  Humans  Outcome Assessment, Health Care  Reproducibility of Results  Reversal Learning/physiology  Autism spectrum disorder  Cognitive flexibility  Outcome measurement  Reversal learning  training (RS, LS). Index. décimale : PER Périodiques Résumé : Cognitive flexibility deficits are a hallmark feature of autism spectrum disorder (ASD), but few evidence-based behavioral interventions have successfully addressed this treatment target. Outcome measurement selection may help account for previous findings. The probabilistic reversal learning task (PRL) is a measure of cognitive flexibility previously validated for use in ASD, but its use as an outcome measure has not yet been assessed. The current study examined the feasibility, reproducibility, and sensitivity of PRL in a within-subjects trial of Regulating Together, a group-based intervention targeting emotion regulation. We demonstrated the PRL is highly feasible, showed test-retest reproducibility, and is sensitive to detect change following the intervention. Our findings demonstrate the PRL task may be a useful outcome measure of cognitive flexibility in future intervention trials in ASD. En ligne : http://dx.doi.org/10.1007/s10803-021-05288-y Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=486

Divergent aperiodic slope and alpha dynamics expose cortical excitability gradients in fragile X syndrome / Rana ELMAGHRABY in Molecular Autism, 16 (2025)  

Public ISBD [article]  inMolecular Autism > 16 (2025) . - 49 Titre : Divergent aperiodic slope and alpha dynamics expose cortical excitability gradients in fragile X syndrome Type de document : texte imprimé Auteurs : Rana ELMAGHRABY, Auteur ; Yanchen LIU, Auteur ; Priya RAMESH, Auteur ; Grace WESTERKAMP, Auteur ; Meredith A. NELSON, Auteur ; Travis LARSH, Auteur ; Elizabeth SMITH, Auteur ; Donald L. GILBERT, Auteur ; Steve W. WU, Auteur ; Craig A. ERICKSON, Auteur ; Ernest V. PEDAPATI, Auteur ; Rana ELMAGHRABY, Auteur ; Yanchen LIU, Auteur ; Priya RAMESH, Auteur ; Grace WESTERKAMP, Auteur ; Meredith A. NELSON, Auteur ; Travis LARSH, Auteur ; Elizabeth SMITH, Auteur ; Donald L. GILBERT, Auteur ; Steve W. WU, Auteur ; Craig A. ERICKSON, Auteur ; Ernest V. PEDAPATI, Auteur Article en page(s) : 49 Langues : Anglais (eng) Mots-clés : Humans  Fragile X Syndrome/physiopathology  Male  Female  Cortical Excitability/physiology  Young Adult  Adult  Electroencephalography  Adolescent  Alpha Rhythm  Case-Control Studies  Aperiodic slope  Cortical excitability  Eeg  Fragile X syndrome  Sex differences  Source localization  SpecParam Index. décimale : PER Périodiques Résumé : BACKGROUND: Fragile X syndrome (FXS) is characterized by cortical hyperexcitability, a core neurophysiological feature that contributes to sensory hypersensitivity, cognitive dysfunction, and other disabling symptoms. This disruption in excitatory-inhibitory balance is a key pharmacological target, yet reliable biomarkers to quantify it noninvasively remain limited. Spectral slope, derived from the aperiodic component of the EEG power spectrum, has emerged as a potential index of cortical excitability. Here, we evaluated spectral slope and theta-alpha peak frequency in individuals with FXS to assess their utility as candidate neurophysiological biomarkers. METHODS: Five minutes of resting state EEG data were collected from 70 subjects with FXS (mean age 20.5 ± 10 years; 32 females) and 71 age-matched controls (mean age 22.2 ± 10.7 years; 30 females). The Spectral Parameterization toolbox (SpecParam) was used to separate periodic and aperiodic components of the source localized power spectra and characterize aperiodic slope and theta-alpha peak frequency. RESULTS: Statistical modeling of aperiodic slope revealed a significant two-way interaction between sex and diagnostic group, but no interaction with brain lobe. Among males, the aperiodic slope was significantly decreased in FXS, indicating greater cortical excitability, compared to typically developing controls (TDC), whereas no difference was observed between FXS and TDC females. For peak alpha frequency, statistical modeling identified significant two-way interactions between sex and diagnostic group, and between brain lobe and diagnostic group, but no significant three-way interaction. LIMITATIONS: This study is limited by the absence of non-invasive measures of cortical fragile X mental retardation protein (FMRP). Additionally, participants were not stratified by mosaic status and FMRP levels were not quantified, which could affect variability and interpretation. CONCLUSION: Compared to traditional band-limited power measures, aperiodic slope provides a more direct and validated index of excitation-inhibition balance. Our findings of reduced aperiodic slope in male subjects with FXS align with preclinical circuit-level evidence of increased excitability in FXS and are consistent with previous findings of reduced individual alpha peak frequency, supporting with thalamocortical dysrhythmia models of FXS. Importantly, aperiodic slope measurements can be applied directly to various modalities of local field potential data, enabling more robust cross-species and translational comparisons. En ligne : https://dx.doi.org/10.1186/s13229-025-00682-0 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=569 [article] Divergent aperiodic slope and alpha dynamics expose cortical excitability gradients in fragile X syndrome [texte imprimé] / Rana ELMAGHRABY, Auteur ; Yanchen LIU, Auteur ; Priya RAMESH, Auteur ; Grace WESTERKAMP, Auteur ; Meredith A. NELSON, Auteur ; Travis LARSH, Auteur ; Elizabeth SMITH, Auteur ; Donald L. GILBERT, Auteur ; Steve W. WU, Auteur ; Craig A. ERICKSON, Auteur ; Ernest V. PEDAPATI, Auteur ; Rana ELMAGHRABY, Auteur ; Yanchen LIU, Auteur ; Priya RAMESH, Auteur ; Grace WESTERKAMP, Auteur ; Meredith A. NELSON, Auteur ; Travis LARSH, Auteur ; Elizabeth SMITH, Auteur ; Donald L. GILBERT, Auteur ; Steve W. WU, Auteur ; Craig A. ERICKSON, Auteur ; Ernest V. PEDAPATI, Auteur . - 49. Langues : Anglais (eng) in Molecular Autism > 16 (2025) . - 49 Mots-clés : Humans  Fragile X Syndrome/physiopathology  Male  Female  Cortical Excitability/physiology  Young Adult  Adult  Electroencephalography  Adolescent  Alpha Rhythm  Case-Control Studies  Aperiodic slope  Cortical excitability  Eeg  Fragile X syndrome  Sex differences  Source localization  SpecParam Index. décimale : PER Périodiques Résumé : BACKGROUND: Fragile X syndrome (FXS) is characterized by cortical hyperexcitability, a core neurophysiological feature that contributes to sensory hypersensitivity, cognitive dysfunction, and other disabling symptoms. This disruption in excitatory-inhibitory balance is a key pharmacological target, yet reliable biomarkers to quantify it noninvasively remain limited. Spectral slope, derived from the aperiodic component of the EEG power spectrum, has emerged as a potential index of cortical excitability. Here, we evaluated spectral slope and theta-alpha peak frequency in individuals with FXS to assess their utility as candidate neurophysiological biomarkers. METHODS: Five minutes of resting state EEG data were collected from 70 subjects with FXS (mean age 20.5 ± 10 years; 32 females) and 71 age-matched controls (mean age 22.2 ± 10.7 years; 30 females). The Spectral Parameterization toolbox (SpecParam) was used to separate periodic and aperiodic components of the source localized power spectra and characterize aperiodic slope and theta-alpha peak frequency. RESULTS: Statistical modeling of aperiodic slope revealed a significant two-way interaction between sex and diagnostic group, but no interaction with brain lobe. Among males, the aperiodic slope was significantly decreased in FXS, indicating greater cortical excitability, compared to typically developing controls (TDC), whereas no difference was observed between FXS and TDC females. For peak alpha frequency, statistical modeling identified significant two-way interactions between sex and diagnostic group, and between brain lobe and diagnostic group, but no significant three-way interaction. LIMITATIONS: This study is limited by the absence of non-invasive measures of cortical fragile X mental retardation protein (FMRP). Additionally, participants were not stratified by mosaic status and FMRP levels were not quantified, which could affect variability and interpretation. CONCLUSION: Compared to traditional band-limited power measures, aperiodic slope provides a more direct and validated index of excitation-inhibition balance. Our findings of reduced aperiodic slope in male subjects with FXS align with preclinical circuit-level evidence of increased excitability in FXS and are consistent with previous findings of reduced individual alpha peak frequency, supporting with thalamocortical dysrhythmia models of FXS. Importantly, aperiodic slope measurements can be applied directly to various modalities of local field potential data, enabling more robust cross-species and translational comparisons. En ligne : https://dx.doi.org/10.1186/s13229-025-00682-0 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=569

Health Related Quality of Life in Autistic Youth and Their Families / Rebecca C. SHAFFER ; Lauren M. SCHMITT ; Marika C. COFFMAN ; Paul S. HORN ; Debra L. REISINGER ; Craig A. ERICKSON in Journal of Autism and Developmental Disorders, 55-6 (June 2025)  

Permalink

Latent Class Analysis Identifies Distinctive Behavioral Subtypes in Children with Fragile X Syndrome / Melissa RASPA ; Carla M. BANN ; Julia M. GABLE ; Holly K. HARRIS ; Dejan B. BUDIMIROVIC ; Reymundo LOZANO ; Elizabeth BERRY-KRAVIS ; Milen VELINOV ; Amy L. TALBOY ; Stephanie L. SHERMAN ; Walter E. KAUFMANN ; Marcy SCHUSTER ; Nicole TARTAGLIA ; Robyn A. FILIPINK ; Dejan B. BUDIMIROVIC ; Deborah BARBOUTH ; Amy LIGHTBODY ; Allan REISS ; Carol M. DELAHUNTY ; Randi J. HAGERMAN ; David HESSL ; Craig A. ERICKSON ; Gary FELDMAN ; Jonathan D. PICKER ; Ave M. LACHIEWICZ ; Holly K. HARRIS ; Amy ESLER ; Richard E. FRYE ; Patricia A. EVANS ; Mary Ann MORRIS ; Barbara A. HAAS-GIVLER ; Andrea L. GROPMAN ; Ryan S. UY ; Carie M. BUCHANAN ; Jean A. FRAZIER ; Stephanie M. MORRIS ; Forward CONSORTIUM in Journal of Autism and Developmental Disorders, 54-2 (February 2024)  

Permalink

Patterns in Medication Use for Treatment of Depression in Autistic Spectrum Disorder / Ernest V. PEDAPATI ; Kelli C. DOMINICK ; Katherine HARRIS ; Martine LAMY ; Cara FOSDICK ; Lauren SCHMITT ; Rebecca C. SHAFFER ; Elizabeth SMITH ; Meredith WILL ; Christopher J. MCDOUGLE ; Craig A. ERICKSON in Journal of Autism and Developmental Disorders, 55-6 (June 2025)  

Permalink

---

1 (1 - 8 / 8) Par page : 25 50 100 200